
Beijing Airdoc Technology Co., Ltd.
2251.HKHKSEHealthcareMedical - Diagnostics & Research
Latest quote
HK$9.57
−HK$0.83 · -7.98%
2251.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteBeijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Da Lei Zhang
- Listed since
- Nov 5, 2021
- Employees
- 181
Market position
52-week range
Current HK$9.57
- Open
- HK$9.57
- Previous close
- HK$10.40
- Volume
- 100
- 0× average
- Average volume
- 45.2K
- Average daily volume
- Market cap
- 966.87M HKD
- Beta
- 0.8
- Market reference 1
- 50-day average
- HK$10.3792
- -7.80% below average
- 200-day average
- HK$11.3465
- -15.66% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -34.7×
- P/B (TTM)
- 0.69×
- P/S (TTM)
- 4.78×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 73.53%
- Operating margin
- -20.99%
- Net margin
- -14.41%
Financial health
- Debt / equity
- 0.02×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 173.26M HKD | 156.37M HKD | 203.96M HKD | 113.66M HKD | 115.18M HKD |
| Cost of goods sold | 45.94M HKD | 69.69M HKD | 78.83M HKD | 57.81M HKD | 44.94M HKD |
| Gross profit | 127.33M HKD | 86.68M HKD | 125.13M HKD | 55.85M HKD | 70.24M HKD |
| Research and development | 58.1M HKD | 101.69M HKD | 111.64M HKD | 125.59M HKD | 64.27M HKD |
| Selling, general, and administrative | 105.6M HKD | 186.81M HKD | 199.63M HKD | 180.08M HKD | 149.65M HKD |
| Operating expenses | 163.7M HKD | 327.7M HKD | 311.27M HKD | 298.63M HKD | 211.02M HKD |
| Interest income | 14.6M HKD | 15.24M HKD | 13.02M HKD | 9.14M HKD | 2.02M HKD |
| Interest expense | 336.07K HKD | 229K HKD | 545K HKD | 439K HKD | 298K HKD |
| Depreciation and amortization | 20.24M HKD | 23.48M HKD | 31.95M HKD | 22.67M HKD | 15.5M HKD |
| Operating income | −36.37M HKD | −201.83M HKD | −186.14M HKD | −241.38M HKD | −142.23M HKD |
| Net income | −24.98M HKD | −255.46M HKD | −132.53M HKD | −180M HKD | −142.63M HKD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.24
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
2251.HK peers
Continue in GoAI
Research 2251.HKresearch.disclaimer





